This pilot phase will determine the feasibility of enrolment of patients to a stroke prevention trial within 24 hours of symptom onset and to assess the occurrence of adverse events and laboratory safety of early treatment initiation.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Clopidogrel (Plavix®)Drug
Other Names: Plavix, Clodelib, Clovelen Intervention Desc: Antiplatelet agent
- Simvastatin Drug
Intervention Desc: HMG-CoA reductase inhibitor; lowers cholesterol
Multi-center, randomized, double-blind, controlled trial, 2x2 factorial design.
All patients will be on aspirin. Patients will be randomized to clopidogrel (300mg loading dose + 75mg/day) or placebo and to simvastatin (40mg/day) or placebo within 24 hours of onset of TIA or minor stroke.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Any stroke at 90 days, stroke severity.|
|Secondary||Composite of stroke, myocardial infarction, or vascular death at 90 days.|